Meda Scoops Up Asthma Inhaler Maker For $135M
Acton's Aerospan, an inhaler set to hit the U.S. market at the beginning of next year, is Meda's key to the nation's $2 billion market for inhaled asthma products containing a mono-corticosteroid, as well as other major markets, according to Meda. Aerospan falls within one of Meda's core therapy areas, respiratory, the company said.
"The acquisition of...
To view the full article, register now.